Matches in Nanopublications for { ?s ?p "[Despite increasing use of `targeted therapy,` interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP308523.RAickM_SGDS7HKctIQenDR2zlrLeoTraKoQZyBz2wXZMk130_assertion description "[Despite increasing use of `targeted therapy,` interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308523.RAickM_SGDS7HKctIQenDR2zlrLeoTraKoQZyBz2wXZMk130_provenance.
- NP764326.RAD-ecdX5capIvaRMx0yYy02PZ2unkVGtEphUWfAZoo_0130_assertion description "[Despite increasing use of `targeted therapy,` interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP764326.RAD-ecdX5capIvaRMx0yYy02PZ2unkVGtEphUWfAZoo_0130_provenance.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion description "[Despite increasing use of `targeted therapy,` interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_provenance.